AstraZeneca's Rezield Hits Another Regulatory Wall
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues a second "complete response" letter for the respiratory syncytial virus prophylaxis agent, this time seeking a new clinical trial.